Managing Specimen Integrity

Evaluates specimen adequacy and rejection criteria with pre-analytical quality documentation.

Why This Skill Exists

Pre-analytical errors account for 46-68% of all laboratory errors, and specimen integrity failures are the leading cause. A hemolyzed potassium specimen, a clotted coagulation tube, an unlabeled surgical specimen, or an improperly transported microbiology culture can each produce misleading results that drive incorrect clinical decisions. The economic cost is substantial: recollection disrupts clinical workflows, delays diagnosis, and in some cases (neonatal, oncology, difficult-access patients) recollection may be impossible or harmful.

CLIA 42 CFR 493.1242 requires laboratories to establish specimen submission and handling instructions and define criteria for specimen rejection. CAP accreditation (GEN.40490-40530 series) mandates documented acceptance/rejection criteria, specimen labeling requirements (two patient identifiers), and processes for managing non-conforming specimens. The Joint Commission patient safety goals reinforce two-identifier specimen labeling. This skill provides a systematic framework for evaluating specimen integrity and managing pre-analytical quality.

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Specimen type — Blood (tube type), urine, tissue, body fluid, swab, or other? Default: blood specimen.
2. Test(s) ordered — What analytes are requested? Different tests have different integrity requirements. Default: comprehensive metabolic panel.
3. Issue identified — Hemolysis, lipemia, icterus, clotting, underfill, mislabel, wrong tube, delayed transport, temperature excursion, or other? Default: hemolysis.
4. Patient context — Difficult draw (neonatal, dialysis, oncology), repeated collection issue, stat/urgent request? Default: routine adult.
5. Collection site — Was the specimen drawn from an IV line, port, or direct venipuncture? Default: direct venipuncture.
6. Time since collection — How long has the specimen been in transit or storage? Default: < 2 hours.
7. Recollection feasibility — Can a new specimen be obtained without significant burden? Default: yes.

Documents to Request

• Specimen requisition form with two identifiers
• Collection time and collector identity
• Transport conditions (temperature, time in transit)
• Tube type and anticoagulant verification
• Hemolysis/lipemia/icterus index from analyzer (if quantified)
• Institutional specimen acceptance/rejection criteria policy
• Test-specific specimen requirements (stability, tube type, volume)
• Non-conforming specimen log

Step 1: Specimen Identification and Labeling Verification

Verify specimen labeling per CAP and Joint Commission requirements:

Minimum labeling requirements (CAP GEN.40490):

• Two unique patient identifiers (name + DOB, name + MRN, or equivalent)
• Date of collection
• Time of collection (required for time-sensitive analytes)
• Collector identification
• Specimen source/type (for non-blood specimens)

Rejection criteria for labeling deficiencies:

Exception: Surgical pathology and cytology specimens may have a reconciliation process per CAP ANP.11700, but the two-identifier requirement still applies.

Step 2: Specimen Condition Assessment

Evaluate the physical condition of the specimen:

Hemolysis Index (Chemistry Analyzers)

Lipemia Index

Icterus Index

Step 3: Tube Type and Volume Verification

Confirm correct tube type and adequate fill volume:

Common tube types and requirements:

Rejection criteria for tube/volume issues:

Step 4: Stability and Transport Assessment

Evaluate whether specimen stability requirements were met:

Critical stability windows:

Step 5: Non-Conforming Specimen Management and Documentation

When a specimen is rejected or has quality issues, follow a structured process:

1. Document the issue: Record the specific non-conformance (hemolysis, clot, mislabel, etc.) in the LIS.
2. Notify the collector/ordering provider: Per institutional policy, communicate the rejection reason and recollection instructions.
3. Partial reporting: When possible, report unaffected analytes from the specimen and reject only those analytes affected by the integrity issue. Add interpretive comments.
4. Log the non-conformance: Enter into the non-conforming specimen tracking system for trending.
5. Trend analysis: Review non-conformance data monthly. Identify patterns by collector, unit, specimen type, or time of day. Target QI interventions to reduce the most common and impactful errors.
6. Education and feedback: Provide targeted education to collection staff when trends are identified. Document training and re-competency assessment.

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was specimen labeling verified against the two-identifier requirement before any testing?
2. Were hemolysis, lipemia, and icterus indices quantified and applied to analyte-specific rejection criteria?
3. Was tube type confirmed as correct for all ordered tests?
4. Were stability requirements assessed based on collection time and transport conditions?
5. Was the non-conforming specimen documented in the tracking system with collector notification?

Quality Audit

• Two patient identifiers verified on specimen label
• Collection date, time, and collector identity documented
• Hemolysis/lipemia/icterus index quantified by analyzer
• Analyte-specific rejection thresholds applied (not blanket rejection)
• Tube type correct for all ordered tests
• Citrate tube fill volume verified (>= 90% for coagulation)
• Specimen transported within stability requirements
• Temperature-sensitive specimens transported on ice when required
• Non-conforming specimen logged with specific rejection reason
• Collector/provider notified of rejection with recollection instructions
• Monthly trending of non-conformance data performed
• QI interventions documented for identified trends
• Institutional acceptance/rejection criteria policy current and accessible
• Staff competency for specimen assessment documented annually

Guidelines

• Never process an unlabeled specimen regardless of urgency — this is a non-negotiable patient safety requirement per CAP and Joint Commission
• Quantify hemolysis, lipemia, and icterus using the analyzer's serum index system rather than visual estimation; visual assessment is unreliable and not auditable
• Apply analyte-specific rejection thresholds rather than blanket specimen rejection; many analytes are unaffected by mild hemolysis, and rejecting the entire panel wastes clinical resources
• For citrate tubes (coagulation testing), reject any tube less than 90% filled; the altered blood-to-citrate ratio produces unreliable PT and PTT results regardless of how "close" the fill appears
• Separate serum/plasma from cells within 1 hour of collection for potassium and other cell-sensitive analytes; delayed separation is the most common cause of pseudohyperkalemia
• Track non-conforming specimens by collector, unit, and specimen type; use the data for targeted quality improvement rather than punitive action
• When recollection is impossible or poses significant patient burden (neonatal, difficult access), consult with the laboratory director about reporting with appropriate qualifiers and comments
• Review and update institutional acceptance/rejection criteria at least annually and whenever new tests or specimen types are introduced